Menu
Search
|

Menu

Close
X

Amicus Therapeutics Inc FOLD.OQ (NASDAQ Stock Exchange Global Market)

15.50 USD
-0.25 (-1.59%)
As of 2:30 PM EDT
chart
Previous Close 15.75
Open 15.67
Volume 224,218
3m Avg Volume 786,102
Today’s High 15.75
Today’s Low 15.16
52 Week High 17.60
52 Week Low 11.45
Shares Outstanding (mil) 188.47
Market Capitalization (mil) 2,968.43
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
17
FY17
37
FY16
5
FY15
0
EPS (USD)
FY18
-0.284
FY17
-0.843
FY16
-1.487
FY15
-1.186
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
60.02
8.07
Price to Book (MRQ)
vs sector
5.68
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
31.97
17.39
LT Debt to Equity (MRQ)
vs sector
31.97
13.21
Return on Investment (TTM)
vs sector
-14.16
13.23
Return on Equity (TTM)
vs sector
-27.45
15.28

EXECUTIVE LEADERSHIP

John Crowley
Chairman of the Board, Chief Executive Officer, Since 2011
Salary: $601,037.00
Bonus: $299,316.00
Bradley Campbell
President, Chief Operating Officer, Director, Since 2018
Salary: $427,450.00
Bonus: $177,392.00
William Baird
Chief Financial Officer, Since 2012
Salary: $396,550.00
Bonus: $131,655.00
Daphne Quimi
Senior Vice President - Finance and Administration, Corporate Controller, Since 2015
Salary: $207,508.00
Bonus: $39,889.00
Kurt Andrews
Senior Vice President - Human Resources, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1 Cedarbrook Dr
CRANBURY   NJ   08512-3618

Phone: +1609.6622000

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

SPONSORED STORIES